"TECVAYLI is the most utilized BCMA bispecific in later lines of myeloma treatment, supported by extensive clinical and real-world evidence. These results demonstrate the clinical benefits of TECVAYLI ...
First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as second line Independent Data Monitoring Committee ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback